NCT02115347View on ClinicalTrials.gov

Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 19, 2014

Primary Completion Date

January 10, 2015

Study Completion Date

January 19, 2015

Conditions
Type 2 Diabetes MellitusHepatic Impairment
Interventions
DRUG

Ertugliflozin 15 mg

Tablet

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02115347 - Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014) | Biotech Hunter | Biotech Hunter